$24.17
3.25% yesterday
Nasdaq, May 20, 07:47 pm CET
ISIN
US05455M1009
Symbol
TECX
Sector
Industry

AVROBIO Inc Stock price

$24.56
+6.64 37.05% 1M
-19.47 44.22% 6M
-21.61 46.81% YTD
+7.88 47.24% 1Y
+15.07 158.74% 3Y
-179.68 87.97% 5Y
-349.84 93.44% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.15 4.91%
ISIN
US05455M1009
Symbol
TECX
Sector
Industry

Key metrics

Market capitalization $458.60m
Enterprise Value $154.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.52
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-63.35m
Free Cash Flow (TTM) Free Cash Flow $-64.78m
Cash position $306.25m
EPS (TTM) EPS $-7.31
P/E forward negative
Short interest 11.34%
Show more

Is AVROBIO Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

AVROBIO Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a AVROBIO Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a AVROBIO Inc forecast:

Buy
100%

Financial data from AVROBIO Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 1.56 1.56
77% 77%
-
-1.56 -1.56
77% 77%
-
- Selling and Administrative Expenses 17 17
20% 20%
-
- Research and Development Expense 43 43
40% 40%
-
-62 -62
16% 16%
-
- Depreciation and Amortization 1.56 1.56
77% 77%
-
EBIT (Operating Income) EBIT -63 -63
17% 17%
-
Net Profit -59 -59
294% 294%
-

In millions USD.

Don't miss a Thing! We will send you all news about AVROBIO Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVROBIO Inc Stock News

Neutral
GlobeNewsWire
4 days ago
WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardi...
Neutral
GlobeNewsWire
12 days ago
WATERTOWN, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2025, and provided an overview o...
Positive
Seeking Alpha
28 days ago
We initiate a Buy rating on Tectonic Therapeutic due to promising data for TX45. TX45 showed positive interim Phase 1b results, but the APEX Phase 2 trial with 180 patients will be crucial for validating its efficacy and safety. TX2100 targets hereditary hemorrhagic telangiectasia with promising preclinical data, aiming for a Phase 1 launch in late 2025 or early 2026.
More AVROBIO Inc News

Company Profile

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alise Reicin
Employees 51
Founded 2015
Website www.tectonictx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today